

Table I. Clinical features of patients with primary vitreoretinal lymphoma (PVRL).

Case	Age, years	Eye	Gender	Prior treatments	IL10, pg/ml	IL6, pg/ml	IgH	Cytology	TSI, months	Dissemination	Symptoms of systemic involvement	Treatment for PVRL	Follow-up, months	Status at study end
1	83	L	M	SC	1,300	51.6	-	+	6	CNS	Facial deformity	RT	40	Alive
2	65	B	F	SC	50	19.8	+	+	6	CNS	Asymptomatic	Radiation+ IV-MTX	78	Dead
3	72	R	F	SC	5,430	155	+	+	17	Systemic	Lymph node swelling	RT	76	Alive
4	56	B	M	SC	1,930	21.6	+	-	4	CNS	Asymptomatic	HD-MTX→R-MPV	124	Dead
5	51	R	M	None	14,900	65	+	+	3	CNS	Dysarthria	HD-MTX+ WB-RT	116	Alive
6	80	L	F	SC	308	108	+	-	-	-	-	RT	11	Alive
7	69	L	F	None	21,100	56.5	-	+	9	CNS	Dementia	RT	63	Alive
8	82	R	M	LC	10	121	+	-	-	-	-	IV-MTX	161	Alive
9	75	B	M	LC injection	60	9.3	+	+	-	-	-	IV-MTX	8	Alive
10	48	B	F	SC injection	128	25.2	+	+	43	CNS	Dementia	WB-RT+ R-MVP→IV-MTX, AraC	43	Alive
11	59	L	F	LC injection	2,000	41.9	-	+	-	-	-	IV-MTX	11	Alive
12	72	B	F	LC injection	600	147	+	+	37	CNS	Paralysis	IV-MTX	37	Alive
13	85	B	M	None	166	17.6	+	+	-	-	-	RT+IV-MTX	32	Alive
14	87	B	F	None	1,140	567	+	+	-	-	-	RT+IV-MTX	6	Alive
15	58	B	M	SC	81	9.2	+	+	29	CNS	Falling	IV-MTX	29	Alive
16	47	L	M	None	775	10.4	+	+	9	CNS	Asymptomatic	WB-RT+ R-MPV+AraC+ IV-MTX	48	Alive
17	49	L	F	None	3,430	51	-	+	-	-	-	WB-RT+R-MPV+IV-MTX	46	Alive

AraC: Cytarabine; B: bilateral; CNS: central nervous system. F: female; HD-MTX: intravenous high-dose methotrexate; IgH: immunoglobulin heavy-chain gene rearrangements; IL: interleukin; IV-MTX: intravitreal methotrexate injection; L: left; LC: local corticosteroid; M: male; R: right; R-MPV: rituximab/methotrexate/procarbazine/vincristine; RT: radiotherapy; SC: systemic corticosteroids; TSI: time to systemic involvement; WB-RT: whole-brain radiotherapy.